This invention is referred to the field of medicine, namely preventative treatment, and may be used as a means of synergetic minimization of negative impact of flights on human health (brain, stomach, lungs, blood vessels, heart etc.) with application of known substances and medicines with newly discovered pharmacological properties in new conditions. The ultimate technical solution of this invention would be synergetic minimization of negative impact of flying on human health without foot swelling, belching, jet-lag, tiredness and fatigue etc. The claimed technical result is achieved by the method of synergetic minimization of negative impact of air flights on human health, including consumption of substances that improve osmotic concentration of blood plasma, in the form of oral rehydration solution, split into two intakes as a minimum, first intake in the amount of at least 0.3 liters up to 1 liter before boarding and further during the flight from half an hour to 2 hours at least 0.3 liters to 1 liter and on as-needed basis.

A composition including a hydrate form of magnesium oxide, denoted as MgO.(H.sub.2O)n, at a concentration ranging from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2. The composition may further include MgO at a concentration ranging from 0 to 99 wt %; or Mg(OH).sub.2, at a concentration ranging from 0 to 99 wt %; or Mg(OH).sub.2 at a concentration ranging from 0 to 99 wt %, and MgO, at a concentration ranging from 0 to 99 wt %.

A composition including a hydrate form of magnesium oxide, denoted as MgO.(H.sub.2O)n, at a concentration ranging from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2. The composition may further include MgO at a concentration ranging from 0 to 99 wt %; or Mg(OH).sub.2, at a concentration ranging from 0 to 99 wt %; or Mg(OH).sub.2 at a concentration ranging from 0 to 99 wt %, and MgO, at a concentration ranging from 0 to 99 wt %.

A composition including a hydrate form of magnesium oxide, denoted as MgO.(H.sub.2O)n, at a concentration ranging from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2. The composition may further include MgO at a concentration ranging from 0 to 99 wt %; or Mg(OH).sub.2, at a concentration ranging from 0 to 99 wt %; or Mg(OH).sub.2 at a concentration ranging from 0 to 99 wt %, and MgO, at a concentration ranging from 0 to 99 wt %.

The disclosure relates to a dosage forms and combinations of dosage forms useful for effective oral administration of drugs which are otherwise unsuitable for oral administration, owing to acid- and/or protease-mediated degradation. The dosage forms include a self-microemulsifying drug delivery system (SMEDDS) with which the drug is combined and an antacid. When co-administered to a mammal, the dosage form(s) can prevent drug degradation by the strong acid and digestive enzymes normally present in the gastric environment, and can improve water-soluble drug absorption in gastrointestinal (GI) tract. The dosage forms can be used to effectively administer insulin by an oral route, for example, such as in the form of a powder that can be stored for long periods and reconstituted with water or another fluid shortly before administration.

The disclosure relates to a dosage forms and combinations of dosage forms useful for effective oral administration of drugs which are otherwise unsuitable for oral administration, owing to acid- and/or protease-mediated degradation. The dosage forms include a self-microemulsifying drug delivery system (SMEDDS) with which the drug is combined and an antacid. When co-administered to a mammal, the dosage form(s) can prevent drug degradation by the strong acid and digestive enzymes normally present in the gastric environment, and can improve water-soluble drug absorption in gastrointestinal (GI) tract. The dosage forms can be used to effectively administer insulin by an oral route, for example, such as in the form of a powder that can be stored for long periods and reconstituted with water or another fluid shortly before administration.

A roll-on product, including magnesium hydroxide; propanediol; glycerin and glycine soja (soybean), is advantageously used as a deodorant and/or for transdermal magnesium delivery to the human body. Combinations of a magnesium source (especially magnesium hydroxide), with propanediol, and with glycerin and glycine soja (soybean) are advantageous for transdermal delivery of magnesium to the body via a roll-on product, a stick, a spray, a lotion, etc. Magnesium deficiency is addressed via products easily used by an ordinary consumer for dermal application.

A roll-on product, including magnesium hydroxide; propanediol; glycerin and glycine soja (soybean), is advantageously used as a deodorant and/or for transdermal magnesium delivery to the human body. Combinations of a magnesium source (especially magnesium hydroxide), with propanediol, and with glycerin and glycine soja (soybean) are advantageous for transdermal delivery of magnesium to the body via a roll-on product, a stick, a spray, a lotion, etc. Magnesium deficiency is addressed via products easily used by an ordinary consumer for dermal application.

The invention provides an oral formulation for dietary supplementation comprising a binder and a mineral complex consisting essentially of a natural basaltic deposit having an average particle size ranging from about 10 to about 6000 mesh and comprising about 40 wt. % to about 60 wt. % Si0.sub.2, about 6 wt. % to about 16 wt. % Fe.sub.20.sub.3, about 4 wt. % to about 12 wt. %. CaO, and about 2 wt. % to about 8 wt. % MgO. Methods of formulating and using the aforesaid oral formulation also are provided.

The invention provides an oral formulation for dietary supplementation comprising a binder and a mineral complex consisting essentially of a natural basaltic deposit having an average particle size ranging from about 10 to about 6000 mesh and comprising about 40 wt. % to about 60 wt. % Si0.sub.2, about 6 wt. % to about 16 wt. % Fe.sub.20.sub.3, about 4 wt. % to about 12 wt. %. CaO, and about 2 wt. % to about 8 wt. % MgO. Methods of formulating and using the aforesaid oral formulation also are provided.